Elsevier

Clinical Therapeutics

Volume 27, Issue 1, January 2005, Pages 58-63
Clinical Therapeutics

A multicenter, open-label, sequential study comparingpreferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease

https://doi.org/10.1016/j.clinthera.2005.01.004Get rights and content

Abstract

Background:

Patients with Parkinson's disease (PD) may have difficulty taking their medications for various reasons. In these patients, orally disintegrating tablets (ODTs) can be given without water and may provide greater convenience and ease of use than conventional tablets.

Objective:

This study compared preferences for ODTs with those of the conventional tablet formulation of the antiparkinsonism combination drug carbidopa-levodopa (C.-L.) in subjects with PD.

Methods:

Subjects aged ≥18 years with PD controlledusing a stable dosage of C-L were enrolled in this multicenter, open-label, sequential study. Subjects received their stable dose of conventional C-L for 7 ± 3 days. They were then switched to the same dose of C-L in the ODT formulation for 14.± 3 days. During the last 3 days of each treatment period, subjects were to record in a diary their “on” and “off” times (asymptomatic and symptomatic parkinsonism, respectively) and medication use. On the final day of each treatment period, the Unified Parkinson's Disease Rating Scale (UPDRS) was administered to subjects before the first morning dose and then after dosing when they mentioned they were experiencing the “on” state. A Global Preference Questionnaire (GPQ) was completed by subjects at the end of the study. The primary variable was response to all GPQ items. Secondary variables were changes in UPDRS score and mean amount of “off” time per 24 hours. Adverse effects (AEs) also were monitored.

Results:

Sixty-one subjects (31 men, 30 women; mean[SD] age, 71.8 [8.3] years; mean body weight, 76.2 kg) participated in the study and were included in the AE assessment; 60 completed the study and were included in the efficacy assessment. Twenty-seven subjects (45%) preferred ODTs compared with 12 (20%) who preferred the conventional tablets (P < 0.017). The remaining 21 subjects (35%) had no preference. The attributes of the ODTs that influenced subjects' preference for that formulation included accessibility to medication to treat “off” times (30 [50%]); ease of activities of daily living (28 [47%]); reduced concern about swallowing the medication (27 [45%]); and use for nighttime dosing, ease of compliance with dosing schedule, and feeling less selfconscious about others noticing medication use (each, 25 [42%]) (all, P < 0.001). No statistically significant differences in UPDRS scores in the “on” and “off” states were found between the 2 formulations. The incidence of AEs was statistically similar between the 2 formulations.

Conclusions:

In this small study of ODT C-L versus conventional C-L tablets in these adult subjects with PD, the results suggest that the ODTs may be of value in certain patients with PD, depending on their personal preferences, disease status, and willingness to alter an aspect of their medication use. For selected patients with PD, the ODT C-L formulation may provide increased convenience, ease of use, and rapid access to medication.

References (9)

  • FolsteinM.F. et al.

    “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician

    J Psychiatr Res

    (1975)
  • LeopoldN.A. et al.

    Drug adherence in Parkinson's disease

    Mov Disord

    (2004)
  • AtkinsonM.J. et al.

    Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panelstudy of chronic disease

    Health Qual Life Outcomes

    (2004)
  • AwadA.G. et al.

    Quality of life and new antipsychotics in schizophrenia. Are patients better off?

    Int J Soc Psychiatry

    (1999)
There are more references available in the full text version of this article.

Cited by (39)

  • Challenges and innovations of drug delivery in older age

    2018, Advanced Drug Delivery Reviews
    Citation Excerpt :

    The main advantages with ODTs are ease of handling, convenient to use, self-medication, rapid onset of action and enhance bioavailability due to pre-gastric absorption and most importantly higher acceptability and adherence [108–110]. Older patients suffering from dysphagia, nausea, vomiting, migraine, depression, schizophrenia and Parkinson diseases show a better adherence for ODTs compared with the conventional dosage forms [111–114]. A key limitation in using ODTs in the elderly is the reduction in saliva production with ageing [115], which is likely to impact on ODT disintegration and drug absorption.

  • Patients’ appropriateness, acceptability, usability and preferences for pharmaceutical preparations: Results from a literature review on clinical evidence

    2017, International Journal of Pharmaceutics
    Citation Excerpt :

    In the other studies, conventional tablets were also used as comparator. Patients with neurological pathologies such as Parkinson's disease, schizophrenia or mood disorders showed preference for orodispersible tablets (Bitter et al., 2010; Nausieda et al., 2005; Sajatovic et al., 2013). Liquid-dispersible tablets were more accepted in dysphagic parkinsonian patients (Bayer et al., 1988), patients with breast cancer receiving highly emetogenic chemotherapy showed preference for a film formulation of dexamethasone (Nishigaki et al., 2012) and hemodialysis patients showed preference for a gelcap formulation (Kaplan et al., 2002).

  • Novel methods of drug administration for the treatment and care of older patients

    2016, International Journal of Pharmaceutics
    Citation Excerpt :

    A number of ODTs have been developed for the treatment of conditions that are common in the older population such as pain, depression, Parkinson's disease and Alzheimer's disease (Slavkova and Breitkreutz, 2015), indicating that there is already a considerable body of evidence supporting patient acceptability of such a dosage form and the potential for improvements in adherence. Patient preference for an ODT compared to a conventional oral tablet or capsule has been demonstrated in cases of dysphagia (Carnaby-Mann and Crary, 2005), depression (Wade et al., 2012) and Parkinson's disease (Nausieda et al., 2005), for example. Despite the progression to market, with a number of products already available and used in older people, for example, Aricept® ODT (donepezil) and Parcopa® (carbidopa/levodopa), there remain some aspects of ODTs that may still be improved upon.

View all citing articles on Scopus
View full text